Creating the leading European Specialty Pharma Platform
Company Presentation
March, 2024
Every day > 60.000 people are diagnosed with life-threatening diseases1
At Medios, we are dedicated to timely providing high-quality and efficient treatments to patients with complex diseases
1 Globally; Sources: https://www.unaids.org/en/resources/fact-sheet,https://www.who.int/campaigns/world-hepatitis-day/2021,https://wfh.org/article/wbdr-2022-data-report-published/,https://www.who.int/news/item/03-02-2022-world-cancer-day-closing-the-care-gap;
Diseases: Cancer, hemophilia, HIV, hepatitis. | 2 |
[Specialty Pharma] Complex and cost-intensivetreatment of life-threatening,chronic or rare diseases
e.g. Cancer, hemophilia, HIV, hepatitis
3
"We are creating the leading European Specialty Pharma platform to treat diseases optimally with individualized medicine."
Matthias Gärtner, CEO Medios AG
4
"I work for Medios because I can contribute to patient care that meets the highest quality standards."
1 Medios at a Glance
2 Key Investment Highlights
3 Financials FY 2023
4 Outlook Appendix
5
Medios at a Glance
The leading provider of Specialty Pharma in Germany
#1 in Specialty Pharma
~€1.8bn
Revenue 2023
Partner network
~800
Partner
Pharmacies
Nationwide coverage
with 6 GMP Labs & 2 Warehouses
Highly
Diversified
6
Indications for complex diseases
Comprehensive expertise
512 Employees1
Clear focus
1,000
Specialty Pharmaceuticals
Only Specialty Pharma company listed on FSE2
since 2016
Quality and efficiency
~400,000
Individual Preparations 2023
Status: March 2024 1Average employees I 2FSE = Frankfurt Stock Exchange (Prime Standard), I 3Depending on indications | 6 |
PATIENT-SPECIFIC THERAPIES |
Pharmaceutical compounding |
of patient-specific therapies |
PHARMACEUTICAL SUPPLY |
Pharmaceutical supply of |
finished Specialty Pharma |
medications |
Medios at a Glance
Integrated platform for
Specialty Pharma
- Strategic cross-selling with broad range of indications
- Partner for changing standard and individualized therapies
- Ensuring highest quality standards through integrated nationwide platform of GMP1 and GDP2 facilities
- Efficiency and accessibility due to proven supply network
1 GMP = Good manufacturing practice I 2 GDP = Good distribution practice | 7 |
Medios at a Glance
From a local player to the #1 in Specialty Pharma in Germany
7-fold
Growth of revenue within just 6 years
21.3% p.a.
Organic growth since 2017
#1
In Specialty Pharma via organic growth and M&A
> €2.15bn
Revenue ambition (Outlook 2025)
Revenue (in €m)
CAGR: | ||||||
~38% | ||||||
254 | 328 | 517 | 627 | 1,357 | 1,610 | 1,785 |
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
8
Medios at a Glance
Strong financial results in 2023
~€1.8bn ~€60.5m
+10.8%+10.3%
Net EBITDA
Revenue pre1
Ongoing | 2.5€ | Low CAPEX | ||
positive | +10.1% | |||
operating | EBITDA pre1 | ~€1.3m | ||
cash flow | per share | |||
1 EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as from 2023 additionally for one-time | 9 |
performance-based payments for the acquisition of manufacturing volumes |
Medios at a Glance
Clear strategy to build the leading European Specialty Pharma Platform
Building
the leading
European Specialty Pharma Platform
Continue evolving our Specialty Pharma business in Germany
Expand compounding within Europe to gain continued growth, while increasing profitability
Become a trusted partner for manufacturing of advanced therapies
Target for 2025
- €2.15bn Revenue
- €110m EBITDA pre1
- 5.1% EBITDA pre1 margin
1 EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities and for one-timeperformance-based payments for the
acquisition of compounding volumes as well as from expenses for ERP-System implementation. | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Medios AG published this content on 28 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 April 2024 16:25:02 UTC.